Treatment with Trikafta (elexacaftor/tezacaftor/ivacaftor) eased sinus symptoms and helped stabilize weight without evidence of worsening lung function in people with cystic fibrosis (CF) who had received a lung transplant, a study found. The researchers said the findings show that Trikafta “can be safely incorporated into post–lung transplant care…

A metabolic pathway shared by lung cells and bacteria may help explain two major features of lung disease in people with cystic fibrosis (CF): the gradual thickening of the airways and persistent lung infections. Researchers found that lab-grown human airway cells carrying disease-causing mutations increase their production of pyrimidines,…

Adults with cystic fibrosis (CF) who spent more time in homes with elevated indoor fine-particle levels tended to show changes in circulating inflammatory signaling proteins, a pilot study found. Researchers measured more than 40 signaling proteins and found that a blood marker linked to tissue repair was significantly associated with…

French scientists have found that distinct patterns of DNA methylation — a type of chemical change that influences how genes are used without altering the underlying DNA sequence — are associated with cystic fibrosis (CF), and are also tied to lung function and CF-related diabetes in people with the…

In young children with cystic fibrosis (CF), treatment with Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) may reverse a form of pancreatic damage previously thought irreversible. That’s according to Vertex Pharmaceuticals, Alyftrek’s developer, which presented new data at this year’s North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore…

One year of Trikafta treatment boosted work productivity and daily activities for people with cystic fibrosis (CF), a real-world study from Canada showed. The gains stemmed from improvements in lung function, physical functioning, and the ability to engage in daily responsibilities. “These findings suggest that the clinical benefits…

Kaftrio, a CFTR modulator marketed as Trikafta (elexacaftor/tezacaftor/ivacaftor) in the U.S., was associated with improved lung function and nutritional status in a study. Researchers found only small changes in which microorganisms were present, but larger changes in their activity. Those larger changes included more microbial activity related to butyrate,…

The genetic defect that causes cystic fibrosis (CF) may also directly contribute to the development of pancreatic cancer, a new study done in cell models suggests. Researchers found that pancreatic cancer cells carrying CF-causing mutations grow faster than cancer cells without these mutations, and this growth could be…

GLP-1 receptor agonists (GLP-1RAs), medications commonly used for diabetes and weight loss, may improve lung function in adults with cystic fibrosis-related diabetes (CFRD), according to a small, exploratory study from Australia. After one year of treatment, patients given a GLP-1RA in addition to insulin, the standard CFRD treatment, had significant…

The next-generation triple-combination CFTR modulator Alyftrek can be safely given to children with cystic fibrosis (CF) as young as 2, according to results from a Phase 3 clinical trial. Findings from the trial also suggest that Alyftrek can improve CFTR activity in kids who switch from the first-generation…